Logo image of BLNE

BEELINE HOLDINGS INC (BLNE) Stock Fundamental Analysis

USA - NASDAQ:BLNE - US2778025005 - Common Stock

3.22 USD
+0.1 (+3.21%)
Last: 10/17/2025, 8:00:01 PM
3.26 USD
+0.04 (+1.24%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BLNE. BLNE was compared to 32 industry peers in the Beverages industry. BLNE has a bad profitability rating. Also its financial health evaluation is rather negative. BLNE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BLNE has reported negative net income.
In the past year BLNE has reported a negative cash flow from operations.
BLNE had negative earnings in each of the past 5 years.
In the past 5 years BLNE always reported negative operating cash flow.
BLNE Yearly Net Income VS EBIT VS OCF VS FCFBLNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

BLNE's Return On Assets of -38.45% is on the low side compared to the rest of the industry. BLNE is outperformed by 87.50% of its industry peers.
With a Return On Equity value of -48.27%, BLNE is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -38.45%
ROE -48.27%
ROIC N/A
ROA(3y)-45.89%
ROA(5y)-36.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLNE Yearly ROA, ROE, ROICBLNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

BLNE has a worse Gross Margin (27.70%) than 90.63% of its industry peers.
In the last couple of years the Gross Margin of BLNE has grown nicely.
BLNE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.05%
GM growth 5Y5.13%
BLNE Yearly Profit, Operating, Gross MarginsBLNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

BLNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLNE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLNE has more shares outstanding
Compared to 1 year ago, BLNE has an improved debt to assets ratio.
BLNE Yearly Shares OutstandingBLNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BLNE Yearly Total Debt VS Total AssetsBLNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

BLNE has an Altman-Z score of -0.09. This is a bad value and indicates that BLNE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.09, BLNE is doing worse than 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.12 indicates that BLNE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.12, BLNE is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z -0.09
ROIC/WACCN/A
WACC7.33%
BLNE Yearly LT Debt VS Equity VS FCFBLNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.22 indicates that BLNE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.22, BLNE perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
BLNE has a Quick Ratio of 1.22. This is a normal value and indicates that BLNE is financially healthy and should not expect problems in meeting its short term obligations.
BLNE has a Quick ratio of 1.22. This is in the better half of the industry: BLNE outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 1.22
BLNE Yearly Current Assets VS Current LiabilitesBLNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.69% over the past year.
Looking at the last year, BLNE shows a very negative growth in Revenue. The Revenue has decreased by -29.13% in the last year.
BLNE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.16% yearly.
EPS 1Y (TTM)47.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.53%
Revenue 1Y (TTM)-29.13%
Revenue growth 3Y-32.73%
Revenue growth 5Y-20.16%
Sales Q2Q%41.08%

3.2 Future

BLNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.96% yearly.
The Revenue is expected to grow by 48.40% on average over the next years. This is a very strong growth
EPS Next Y-62.36%
EPS Next 2Y41.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-33.68%
Revenue Next 2Y48.4%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLNE Yearly Revenue VS EstimatesBLNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
BLNE Yearly EPS VS EstimatesBLNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2022 2023 2024 2025 2026 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BLNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 78.92 indicates a quite expensive valuation of BLNE.
Based on the Price/Forward Earnings ratio, BLNE is valued a bit more expensive than 65.63% of the companies in the same industry.
BLNE is valuated expensively when we compare the Price/Forward Earnings ratio to 22.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 78.92
BLNE Price Earnings VS Forward Price EarningsBLNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLNE Per share dataBLNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as BLNE's earnings are expected to grow with 41.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.96%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BLNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEELINE HOLDINGS INC

NASDAQ:BLNE (10/17/2025, 8:00:01 PM)

After market: 3.26 +0.04 (+1.24%)

3.22

+0.1 (+3.21%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryBeverages
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners2.44%
Inst Owner Change0%
Ins Owners11.65%
Ins Owner Change62.8%
Market Cap63.24M
Analysts85.71
Price Target4.59 (42.55%)
Short Float %5.91%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-295.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-61.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 78.92
P/S 10.36
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 3.85
EV/EBITDA N/A
EPS(TTM)-30.32
EYN/A
EPS(NY)0.04
Fwd EY1.27%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.31
BVpS2.78
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.45%
ROE -48.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.7%
FCFM N/A
ROA(3y)-45.89%
ROA(5y)-36.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.05%
GM growth 5Y5.13%
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.65%
Cap/Sales 3.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.22
Quick Ratio 1.22
Altman-Z -0.09
F-Score5
WACC7.33%
ROIC/WACCN/A
Cap/Depr(3y)62.29%
Cap/Depr(5y)46.27%
Cap/Sales(3y)7.25%
Cap/Sales(5y)5.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.53%
EPS Next Y-62.36%
EPS Next 2Y41.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.13%
Revenue growth 3Y-32.73%
Revenue growth 5Y-20.16%
Sales Q2Q%41.08%
Revenue Next Year-33.68%
Revenue Next 2Y48.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-204.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-208.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-329.66%
OCF growth 3YN/A
OCF growth 5YN/A